Medicare Enrolled
Dr. Don Escarzega-Phan, M.D.
Pain Medicine · Arlington, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Escarzega-Phan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Escarzega-Phan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Escarzega-Phan
Dr. Don Escarzega-Phan is a pain medicine specialist in Arlington, TX, with 16 years of NPI registration. Based on federal Medicare data, Dr. Escarzega-Phan performed 11,118 Medicare services across 1,537 unique beneficiaries.
Between the years covered by Open Payments, Dr. Escarzega-Phan received a total of $7,344 from 71 pharmaceutical and/or device companies across 454 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pain medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Escarzega-Phan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 4% volume in TX
$7,344 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,118
Medicare services
Top 4% in TX for pain medicine
1,537
Unique beneficiaries
$32
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~695 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
3,584 | $1 | $30 |
| Hydromorphone injection, up to 4 mg An injection of hydromorphone, an opioid pain medication, with a dosage of up to 4 milligrams. |
2,647 | $3 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,947 | $64 | $180 |
| Morphine sulfate injection for epidural or intrathecal use, 10 mg This procedure involves the injection of preservative-free morphine sulfate into the epidural or intrathecal space. The dosage administered is 10 mg. |
1,376 | $10 | $200 |
| Drug screening test A laboratory test that uses a chemistry analyzer to detect the presence of drugs in a sample. |
259 | $61 | $200 |
| Definitive drug test using GC/MS or LC/MS A definitive drug test that identifies specific drugs and distinguishes between structural isomers using advanced methods like GC/MS or LC/MS. |
259 | $195 | $800 |
| Injection into lower spine canal with imaging guidance A procedure where a substance is injected into the lower part of the spinal canal. The injection is performed using imaging guidance to ensure accurate placement. |
254 | $198 | $750 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
126 | $97 | $272 |
| Spine facet joint injection with imaging guidance, single level An injection is administered into a single facet joint of the lower or sacral spine while using imaging guidance to ensure accurate placement. |
97 | $187 | $526 |
| Spinal drug pump reprogramming and refill A physician electronically adjusts the settings of a spinal drug infusion pump and refills its medication reservoir. |
93 | $71 | $250 |
| Facet joint injection, second level, with imaging guidance An injection into a lower or sacral spine facet joint using imaging guidance for the second level treated. |
93 | $98 | $264 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
88 | $123 | $419 |
| Spinal injection with imaging guidance A procedure where medication is injected into the middle or upper part of the spinal canal. Imaging technology is used to guide the needle to the correct location. |
86 | $201 | $750 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
82 | $57 | $200 |
| Fluoroscopic guidance for needle placement Use of real-time X-ray imaging to guide the precise placement of a needle during a medical procedure. |
82 | $90 | $167 |
| Electronic analysis and reprogramming of spinal drug pump This procedure involves electronically analyzing and reprogramming a spinal canal drug infusion pump. It does not include the surgical insertion or removal of the device. |
45 | $33 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$7,344
Total received (2018-2024)
Avg $1,049/year across 7 years
Top 31% in TX for pain medicine
71
Companies
454
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,344 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$942
2023
$842
2022
$1,194
2021
$1,068
2020
$1,040
2019
$1,225
2018
$1,033
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Collegium Pharmaceutical, Inc.
$895
Nevro Corp.
$602
PFIZER INC.
$531
Abbott Laboratories
$478
Amgen Inc.
$433
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$279
ABBVIE INC.
$262
Lilly USA, LLC
$260
Scilex Pharmaceuticals Inc.
$212
Horizon Therapeutics plc
$205
BIODELIVERY SCIENCES INTERNATIONAL, INC.
$178
Lundbeck LLC
$137
Teva Pharmaceuticals USA, Inc.
$124
BioDelivery Sciences International, Inc.
$119
GlaxoSmithKline, LLC.
$117
AbbVie Inc.
$117
Novartis Pharmaceuticals Corporation
$116
Biohaven Pharmaceutical Holding Company Ltd.
$114
Medtronic USA, Inc.
$99
Boston Scientific Corporation
$98
Curonix LLC
$98
Sunovion Pharmaceuticals Inc.
$96
Allergan, Inc.
$91
Almatica Pharma LLC
$89
SCILEX PHARMACEUTICALS INC.
$88
ARBOR PHARMACEUTICALS, INC.
$86
Medtronic, Inc.
$85
Valinor Pharma, LLC
$81
Merck Sharp & Dohme Corporation
$72
Zyla Life Sciences
$69
Ferring Pharmaceuticals Inc.
$69
DePuy Synthes Sales Inc.
$64
Janssen Pharmaceuticals, Inc
$55
Forte Bio-Pharma LLC
$52
Zyla Life Sciences, Inc.
$50
Daiichi Sankyo Inc.
$42
TerSera Therapeutics LLC
$41
UPSHER-SMITH LABORATORIES LLC
$41
Kowa Pharmaceuticals America, Inc.
$39
Purdue Pharma L.P.
$39
GRT US Holding, Inc.
$38
Kaleo, Inc.
$37
Takeda Pharmaceuticals U.S.A., Inc.
$32
Jazz Pharmaceuticals Inc.
$29
Merck Sharp & Dohme LLC
$29
US WorldMeds, LLC
$28
Insulet Corporation
$28
Arbor Pharmaceuticals, Inc.
$26
Eisai Inc.
$24
Avanir Pharmaceuticals, Inc.
$24
OptiNose US, Inc.
$22
VERTEX PHARMACEUTICALS INCORPORATED
$21
Azurity Pharmaceuticals, Inc.
$20
Xeris Pharmaceuticals, Inc.
$19
SI-BONE, Inc.
$19
FORTE BIO-PHARMA LLC
$18
USWM, LLC
$17
Promius Pharma LLC
$17
Biogen, Inc.
$17
Fidia Pharma USA Inc.
$16
Biohaven Pharmaceuticals, Inc.
$15
IBSA Pharma Inc.
$15
Novo Nordisk Inc
$14
Upsher-Smith Laboratories LLC
$14
Amarin Pharma Inc.
$14
Assertio Therapeutics, Inc.
$13
Currax Pharmaceuticals LLC
$12
Stimwave Technologies Incorporated
$12
Optinose US, Inc.
$11
AbbVie, Inc.
$11
Virtus Pharmaceuticals LLC
$11
Top 3 companies account for 27.6% of total payments
Associated products mentioned in payments ›
ADUHELM · AIMOVIG · AJOVY · Aimovig · Amitiza · BELBUCA · BELSOMRA · BREO · BUNAVAIL · BUNAVAIL 2.1 mg 30-count box · Belbuca · COLOGUARD DNA CAPTURE REAGENTS · COMIRNATY · CONTRAVE · CREON · DUEXIS · Dayvigo · EMGALITY · EUFLEXXA · Evzio · FLECTOR · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · GENERAL - PAIN MANAGEMENT · GRALISE · GVOKE PFS · Gralise · HORIZANT · HYMOVIS · Horizant · Humira · INJECTAFER · INTELLIS · INTELLIS ADAPTIVESTIM · IONICRF · JANUVIA · LEVORPHANOL TARTRATE · LICART · LINZESS · LONHALA MAGNAIR · LYRICA · Livalo · Lucemyra/Lofexidine · MONOVISC · MOVANTIK · Morphabond ER · NALOCET · NAPRELAN · NT1100 NT2000iX Simplicity · NUEDEXTA · NURTEC ODT · Omnia · Omnipod · PAXLOVID · PENNSAID · PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A · PRIALT · PROCLAIM · PROLATE · Prialt · Proclaim Family of SCS IPGs · Proclaim IPG · QULIPTA · Qutenza · RAYOS · RELISTOR · RELISTOR ORAL · REYVOW · SCS IPGs · SHINGRIX · SPECTRA WAVEWRITER · SPRIX · STEGLATRO · SYMJEPI · SYMPROIC · SYNCHROMED · SYNCHROMEDII · Seglentis · Senza · Senza Spinal Cord Stimulation System · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · UBRELVY · VRAYLAR · VYEPTI · Vascepa · WaveWriter Alpha Prime 16 · XARELTO · XIFAXAN · XTAMPZA · XTAMPZAER · Xhance · Xtampza ER · XtampzaER · ZAVZPRET · ZEMBRACE SYMTOUCH · ZORVOLEX · ZTLido · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH · iFuse Implant
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $66 per 100 Medicare services performed
Geographic Context
Pain medicines within 10 mi
80
Per 100K population
3.7
County median income
$81,905
Nearest hospital
TEXAS HEALTH ARLINGTON MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Escarzega-Phan is a clinical cardiology specialist, with above-average Medicare volume (top 4% in TX), with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Escarzega-Phan experienced with steroid injection (triamcinolone)?
Based on Medicare claims data, Dr. Escarzega-Phan performed 3,584 steroid injection (triamcinolone) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Escarzega-Phan receive payments from pharmaceutical companies?
Yes. Dr. Escarzega-Phan received a total of $7,344 from 71 companies across 454 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Escarzega-Phan's costs compare to other pain medicines in Arlington?
Dr. Escarzega-Phan's average Medicare payment per service is $32. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Escarzega-Phan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Pain Medicines in Arlington
Browse pain medicines in Arlington ranked by procedure volume and transparency data.
Highest volume
Top Pain Medicines in TX
Pain medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pain Medicines in TX
Which TX pain medicines receive the most from drug and device companies.
By company
Collegium Pharmaceutical, Inc. Payments to Doctors
See all physicians who received payments from Collegium Pharmaceutical, Inc.
By company
Nevro Corp. Payments to Doctors
See all physicians who received payments from Nevro Corp.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology